Breast cancers detected by screening mammography do not spontaneously disappear.
Untreated breast cancers detected on screening mammography do not spontaneously disappear or regress, according to a study published in the Journal of the American College of Radiology. Researchers from New York, Texas, Missouri, and California performed a prospective cohort study to investigate the natural history of untreated screen-detected breast cancer to determine if there was validity in claims that breast cancer is over-diagnosed with regular screening and that some of these cancers would regress or disappear if left untreated. The researchers received completed surveys from 42 Society of Breast Imaging fellows in December 2016, with outcomes data from their screening mammography practices. The results showed among all practices, 25,281 screen-detected invasive breast cancers and 9,360 cases of screen-detected ductal carcinoma in situ were reported over the past 10 years. Among these cancers, there were 240 cases of untreated invasive breast cancer and 239 cases of untreated ductal carcinoma in situ, among which zero were reported to have spontaneously disappeared or regressed at next mammography. The researchers concluded among the 479 untreated breast cancers detected on screening mammography, none spontaneously disappeared or regressed. They acknowledged an unknown percentage of these cancers represent over-diagnosis, but because all untreated screen-detected cancers were visible and suspicious for malignancy at next mammographic examination, delaying the onset of screening or increasing the interval between screenings should not reduce the frequency of over-diagnosis.
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.
Is the Kaiser Score More Effective than BI-RADS for Assessing Contrast-Enhanced Mammography and MRI?
October 14th 2024For women with breast-enhanced masses, Kaiser scoring (KS) demonstrated a 20 percent higher AUC than BI-RADS classification for contrast-enhanced mammography (CEM) and was comparable to KS for breast MRI.
FDA Clears New Features in AI-Powered Mammography Software Suite
October 11th 2024Therapixel’s MammoScreen suite has received 510(k) FDA clearances for a breast density assessment feature and updated software that includes automated pre-reporting, which reportedly expedites reporting of mammography findings.